Elutia (ELUT)
Market Price (2/15/2026): $1.06 | Market Cap: $45.0 MilSector: Health Care | Industry: Life Sciences Tools & Services
Elutia (ELUT)
Market Price (2/15/2026): $1.06Market Cap: $45.0 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Weak multi-year price returns2Y Excs Rtn is -108%, 3Y Excs Rtn is -143% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -89% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 55% | ||
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.8%, Rev Chg QQuarterly Revenue Change % is -9.3% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 20% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -114%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -118% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -64% | ||
| Key risksELUT key risks include [1] significant financial instability and going concern risk due to its poor financial health and high cash burn, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -108%, 3Y Excs Rtn is -143% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -89% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 55% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.8%, Rev Chg QQuarterly Revenue Change % is -9.3% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 20% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -114%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -118% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -64% |
| Key risksELUT key risks include [1] significant financial instability and going concern risk due to its poor financial health and high cash burn, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Strengthened Financial Position from BioEnvelope Sale and Debt Elimination: The closing of the $88 million BioEnvelope business sale to Boston Scientific Corporation in October 2025 significantly bolstered Elutia's financial position. This capital was then utilized to repay the full $26.9 million of outstanding secured debt during the fourth quarter of 2025, which greatly reduced financial risk and interest expenses, leaving the company with a strengthened cash position of $44.3 million (including escrowed proceeds) by the end of 2025.
2. Strategic Focus on High-Potential NXT-41x Program: Following the divestiture, Elutia explicitly pivoted its strategic focus towards the development of its next-generation antibiotic-eluting biomatrix, NXT-41x. This program targets the plastic and reconstructive surgery market, specifically breast reconstruction, which represents an estimated $1.5 billion U.S. market opportunity. This clear strategic direction towards a high-value, unmet medical need provided a compelling growth narrative for investors.
Show more
Stock Movement Drivers
Fundamental Drivers
The 15.5% change in ELUT stock from 10/31/2025 to 2/14/2026 was primarily driven by a 18.7% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.91 | 1.05 | 15.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29 | 28 | -1.2% |
| P/S Multiple | 1.3 | 1.6 | 18.7% |
| Shares Outstanding (Mil) | 42 | 42 | -1.5% |
| Cumulative Contribution | 15.5% |
Market Drivers
10/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| ELUT | 15.5% | |
| Market (SPY) | -0.0% | 7.8% |
| Sector (XLV) | 9.3% | -1.7% |
Fundamental Drivers
The -48.3% change in ELUT stock from 7/31/2025 to 2/14/2026 was primarily driven by a -42.4% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.03 | 1.05 | -48.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29 | 28 | -1.3% |
| P/S Multiple | 2.7 | 1.6 | -42.4% |
| Shares Outstanding (Mil) | 39 | 42 | -9.0% |
| Cumulative Contribution | -48.3% |
Market Drivers
7/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| ELUT | -48.3% | |
| Market (SPY) | 8.2% | 0.4% |
| Sector (XLV) | 21.4% | -6.0% |
Fundamental Drivers
The -67.4% change in ELUT stock from 1/31/2025 to 2/14/2026 was primarily driven by a -66.2% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.22 | 1.05 | -67.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 23 | 28 | 25.8% |
| P/S Multiple | 4.6 | 1.6 | -66.2% |
| Shares Outstanding (Mil) | 33 | 42 | -23.4% |
| Cumulative Contribution | -67.4% |
Market Drivers
1/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| ELUT | -67.4% | |
| Market (SPY) | 14.3% | 4.9% |
| Sector (XLV) | 8.8% | 1.6% |
Fundamental Drivers
The -76.6% change in ELUT stock from 1/31/2023 to 2/14/2026 was primarily driven by a -67.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.49 | 1.05 | -76.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 41 | 28 | -30.6% |
| P/S Multiple | 1.5 | 1.6 | 4.8% |
| Shares Outstanding (Mil) | 14 | 42 | -67.8% |
| Cumulative Contribution | -76.6% |
Market Drivers
1/31/2023 to 2/14/2026| Return | Correlation | |
|---|---|---|
| ELUT | -76.6% | |
| Market (SPY) | 74.0% | 6.8% |
| Sector (XLV) | 23.7% | 3.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELUT Return | -54% | -33% | -49% | 73% | -81% | 37% | -93% |
| Peers Return | 17% | -10% | 3% | 5% | 7% | -8% | 12% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| ELUT Win Rate | 25% | 42% | 50% | 50% | 50% | 50% | |
| Peers Win Rate | 58% | 50% | 52% | 60% | 57% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ELUT Max Drawdown | -70% | -45% | -73% | 0% | -86% | -11% | |
| Peers Max Drawdown | -7% | -26% | -17% | -18% | -13% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABBV, IART, EW.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | ELUT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.1% | -25.4% |
| % Gain to Breakeven | 1352.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -25.7% | -33.9% |
| % Gain to Breakeven | 34.6% | 51.3% |
| Time to Breakeven | 27 days | 148 days |
Compare to MDT, BSX, ABBV, IART, EW
In The Past
Elutia's stock fell -93.1% during the 2022 Inflation Shock from a high on 2/3/2021. A -93.1% loss requires a 1352.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Elutia (ELUT)
AI Analysis | Feedback
Here are 1-2 brief analogies for Elutia (ELUT):
- Elutia is like Integra LifeSciences for regenerative tissue implants.
- Elutia is like Organogenesis for specialized surgical biomaterial scaffolds.
AI Analysis | Feedback
- CanGaroo® Biomaterial Envelope: A porcine-derived extracellular matrix envelope designed to secure and protect implantable cardiac devices, aiding in tissue integration and reducing complications.
- SimpliDerm® Acellular Dermal Matrix: A human acellular dermal matrix used in soft tissue repair, particularly in breast reconstruction, to provide a scaffold for tissue regeneration.
- Neuro-Wrap™ Dural Repair: A resorbable biomaterial patch used as a dural substitute for the repair of the dura mater in cranial and spinal surgical procedures.
AI Analysis | Feedback
Elutia (ELUT) Major Customers
Elutia (ELUT) sells primarily to other companies within the healthcare sector.
Their major customers are a broad base of:
- Hospitals
- Surgical centers
- Medical device distributors (both domestic and international)
The company's public filings (e.g., Form 10-K) do not identify any single customer that accounts for 10% or more of its net revenue. This indicates a diversified customer base across numerous healthcare providers and distribution partners rather than reliance on a few specific named companies. Therefore, there are no individually named major customer companies (with or without public symbols) to list.
AI Analysis | Feedback
nullAI Analysis | Feedback
C. Randal Mills, Ph. D. President and Chief Executive Officer
Dr. C. Randal Mills is a co-founder of Elutia (formerly Aziyo Biologics, Inc.) and has served as its President and Chief Executive Officer since June 2022. He is recognized for leading pioneering biotechnology organizations that have generated over $1 billion in shareholder value. Dr. Mills co-founded Incyte (NASDAQ: INCY) in 1991, serving as its chief scientific officer, president, and chairman. In 2000, he co-founded Genomic Health (IPO: GHDX), leading it as CEO for nine years, with a focus on improving treatment decisions for cancer patients. He also co-founded Invitae Corporation (IPO: NVTA) in 2012, where he served as CEO and later Executive Chairman. Additionally, Dr. Mills is the co-founder and Chairman of the Board of Genome Medical and is the CEO of Thinking Bench Capital, LLC.
Matthew B. Ferguson Chief Financial Officer
Matthew B. Ferguson has served as Elutia's Chief Financial Officer since September 2020. Prior to joining Elutia, he was the Chief Financial Officer for Bossa Nova Robotics, a privately held robotics company, from September 2018 to July 2020. From January 2011 to August 2018, Mr. Ferguson held various management positions, including Chief Financial Officer, Chief Business Officer, and Co-President, at Avinger, Inc., a publicly traded cardiovascular medical device company.
Kevin Rakin Executive Chairman
Kevin Rakin is a co-founder of Elutia and has served as its Executive Chairman since November 2015. Mr. Rakin is also a co-founder and General Partner of HighCape Partners, an investment fund and an affiliate of Elutia, since 2013. He has been the Chief Executive Officer of HighCape Capital Acquisition Corp., a publicly traded affiliate of HighCape Partners, since June 2020. Since 2014, Mr. Rakin has been a member of the board of directors of Oramed Pharmaceuticals Inc., a publicly traded pharmaceutical company.
Michelle LeRoux Williams, Ph. D. Chief Scientific Officer
Dr. Michelle LeRoux Williams is the Chief Scientific Officer of Elutia and was one of the company's founders. She brings over 20 years of experience in innovative product development. Previously, Dr. Williams served as Chief Scientific Officer of Osiris Therapeutics, where she invented Osteocel®, led the team that secured regulatory approval for the stem cell drug remestemcel-L, and oversaw the development of successful stem cell products like Grafix® and Cartiform®.
Jeff Hamet Senior Vice President of Finance, Treasurer and Secretary
Jeff Hamet serves as Elutia's Senior Vice President of Finance, Treasurer, and Secretary. He has over 25 years of senior-level finance, accounting, and management experience, primarily in the life sciences, medical services, and high-technology industries. From 2013 to 2015, Mr. Hamet was the President and Chief Financial Officer of NeurExpand Brain Center LLC. Prior to that, from 2004 to 2012, he served as Vice President and Corporate Controller of Martek Biosciences Corporation.
AI Analysis | Feedback
Key Risks to Elutia (ELUT)
- Financial Health and Going Concern: Elutia faces significant financial challenges, with its Altman Z-Score indicating a high risk of bankruptcy. The company has demonstrated poor financial strength, short-term obligations exceeding liquid assets, and a high cash burn rate, leading to concerns about its ability to continue as a going concern. While the sale of its BioEnvelope business has improved its financial position and eliminated debt, underlying profitability and a sustainable cash flow remain critical factors for its long-term viability.
- Regulatory Challenges, Product Development, and Market Acceptance: Operating in the medical devices industry, Elutia is exposed to inherent regulatory risks and the continuous need for innovation. The successful development and commercialization of its pipeline products, such as NXT-41, are subject to significant uncertainties. Future success depends heavily on securing regulatory approvals, gaining physician awareness, and achieving widespread acceptance by the medical community for its products.
- Intense Competition: Elutia operates within a highly competitive healthcare sector. Many of its competitors possess longer operating histories, more established product portfolios, and greater financial resources, which could challenge Elutia's ability to gain market share and sustain growth for its products.
AI Analysis | Feedback
The rapid advancement and increasing clinical viability of engineered biomaterials, particularly synthetic matrices, advanced hydrogels, and 3D bioprinted tissues, pose an emerging threat. These technologies offer customizable, potentially more consistent, and scalable alternatives to human-derived tissue allografts like those offered by Elutia. While many are still in various stages of development or early clinical adoption, their trajectory suggests a fundamental shift in regenerative medicine that could reduce long-term reliance on donor-sourced biological materials by providing alternatives with tunable properties, reduced immunogenicity, and potentially lower manufacturing costs.
AI Analysis | Feedback
The addressable market for Elutia's (ELUT) main product, NXT-41x, in breast reconstruction is estimated to be $1.5 billion in the U.S..
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Elutia (ELUT) over the next 2-3 years:- Launch and Commercialization of NXT-41x in Plastic and Reconstructive Surgery: Elutia is actively advancing NXT-41x, a next-generation antibiotic-eluting biomatrix, targeting the substantial $1.5 billion U.S. market for plastic and reconstructive surgery, particularly for addressing infections and complications after mastectomy. The company anticipates FDA clearance of the base matrix in the second half of 2026 and the drug-eluting version in the first half of 2027. The proceeds from the BioEnvelope business sale are being used to fund this development program, indicating a strong strategic focus on this new product.
- Expansion of Commercial Footprint and Direct Sales Initiatives: Following the termination of a distribution partnership in October 2025, Elutia is expanding its commercial footprint. This move, coupled with a return to direct sales for its Cardiovascular products which showed strong growth in Q3 2025, is expected to drive future revenue.
- Growth of Existing Cardiovascular Products: The Cardiovascular segment demonstrated significant growth in the third quarter of 2025, with revenue increasing 68% year-over-year and 28% sequentially. This momentum, following a return to direct sales, is expected to contribute to continued revenue growth.
- Leveraging Drug-Eluting Biomatrix Technology: Elutia's core mission is to develop and commercialize drug-eluting biomatrix products. The company plans to leverage its proven drug-eluting biologics platform to address unmet medical needs. This overarching technological expertise positions them to potentially introduce further innovative products beyond NXT-41x, contributing to sustained growth.
AI Analysis | Feedback
Share Issuance
- In February 2025, Elutia completed a registered direct offering, generating gross proceeds of approximately $15 million from the sale of 5,520,000 shares of Class A common stock and 480,000 prefunded warrants.
- In June 2024, Elutia executed a registered direct offering, selling 3,175,000 shares of Class A common stock and 725,000 prefunded warrants, which yielded approximately $13.26 million in gross proceeds.
- As of August 2025, Elutia satisfied $2.2 million in outstanding royalty obligations to Ligand through the issuance of 1,105,528 shares of its Class A common stock.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Elutia Earnings Notes | 12/16/2025 | |
| Is Elutia Stock Built to Withstand More Downside? | 10/17/2025 | |
| Day 8 of Loss Streak for Elutia Stock with -43% Return (vs. -71% YTD) [9/18/2025] | 09/19/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 75.30 |
| Mkt Cap | 77.5 |
| Rev LTM | 12,617 |
| Op Inc LTM | 2,670 |
| FCF LTM | 2,214 |
| FCF 3Y Avg | 1,533 |
| CFO LTM | 2,821 |
| CFO 3Y Avg | 2,130 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.0% |
| Rev Chg 3Y Avg | 2.9% |
| Rev Chg Q | 7.9% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Mgn LTM | 19.3% |
| Op Mgn 3Y Avg | 18.3% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 18.9% |
| CFO/Rev 3Y Avg | 19.2% |
| FCF/Rev LTM | 14.3% |
| FCF/Rev 3Y Avg | 13.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 77.5 |
| P/S | 4.7 |
| P/EBIT | 22.9 |
| P/E | 29.6 |
| P/CFO | 18.8 |
| Total Yield | 2.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.7% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.9% |
| 3M Rtn | -1.6% |
| 6M Rtn | -11.6% |
| 12M Rtn | -15.0% |
| 3Y Rtn | 13.6% |
| 1M Excs Rtn | -2.7% |
| 3M Excs Rtn | -2.9% |
| 6M Excs Rtn | -15.6% |
| 12M Excs Rtn | -27.6% |
| 3Y Excs Rtn | -53.8% |
Price Behavior
| Market Price | $1.05 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/08/2020 | |
| Distance from 52W High | -68.5% | |
| 50 Days | 200 Days | |
| DMA Price | $0.78 | $1.36 |
| DMA Trend | down | up |
| Distance from DMA | 35.0% | -22.8% |
| 3M | 1YR | |
| Volatility | 110.6% | 90.0% |
| Downside Capture | -91.22 | 45.49 |
| Upside Capture | 111.77 | -62.02 |
| Correlation (SPY) | 9.5% | 4.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.08 | 0.56 | 0.65 | -0.03 | 0.21 | 0.44 |
| Up Beta | 13.80 | 8.79 | 3.64 | 2.05 | -0.13 | -0.37 |
| Down Beta | 1.58 | 0.54 | 2.31 | 0.60 | 1.06 | 1.41 |
| Up Capture | 68% | 200% | -25% | -105% | -30% | 1% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 11 | 23 | 31 | 55 | 114 | 336 |
| Down Capture | -1284% | -436% | -145% | -4% | 59% | 89% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 7 | 16 | 28 | 64 | 125 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELUT | |
|---|---|---|---|---|
| ELUT | -61.3% | 89.7% | -0.66 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 2.1% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 4.9% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | -3.4% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 7.3% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 1.8% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 0.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELUT | |
|---|---|---|---|---|
| ELUT | -38.9% | 94.1% | -0.07 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 4.0% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 4.9% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | -0.2% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 3.2% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 4.6% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 4.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELUT | |
|---|---|---|---|---|
| ELUT | -21.1% | 92.2% | -0.04 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 4.2% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 4.7% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | -0.4% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 3.5% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 5.0% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 4.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -5.0% | -21.2% | -25.3% |
| 8/14/2025 | -6.0% | 2.3% | -43.3% |
| 3/6/2025 | 8.8% | 27.5% | 6.3% |
| 11/14/2024 | -7.0% | 14.9% | 7.8% |
| 8/7/2024 | 8.1% | 16.2% | 50.0% |
| 3/7/2024 | -9.7% | -9.2% | -15.7% |
| 11/13/2023 | 11.6% | 11.0% | 30.8% |
| 8/14/2023 | 6.7% | 20.1% | -15.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 11 | 9 |
| # Negative | 8 | 5 | 7 |
| Median Positive | 8.2% | 13.3% | 7.8% |
| Median Negative | -3.7% | -9.2% | -15.7% |
| Max Positive | 17.6% | 33.6% | 63.0% |
| Max Negative | -9.7% | -21.2% | -52.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/11/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/08/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rakin, Kevin | trusts | Buy | 12192025 | 0.52 | 50,000 | 25,995 | 167,626 | Form | |
| 2 | Colpman, David | Direct | Buy | 12182025 | 0.51 | 12,500 | 6,375 | 15,860 | Form | |
| 3 | Makes, Brigid | Direct | Buy | 12182025 | 0.52 | 25,000 | 13,000 | 14,040 | Form | |
| 4 | Mills, C Randal | PRESIDENT AND CEO | Direct | Buy | 12182025 | 0.51 | 3,000 | 1,530 | 193,394 | Form |
| 5 | Ferguson, Matthew | CHIEF FINANCIAL OFFICER | Direct | Buy | 12182025 | 0.53 | 60,000 | 31,800 | 236,968 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.